Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response

BACKGROUND: Poor drug response of sorafenib is a major challenge which reduces clinical benefit of renal cell carcinoma (RCC) patients. It is therefore of great clinical significance to elucidate the underlying mechanism to restore the therapeutic response to sorafenib. METHODS: Angiopoietin-like pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Yi, Yang, Fu, Liu, Bing, Zhao, Tangliang, Xu, Zhipeng, Xiong, Ying, Sun, Shuhan, Qu, Le, Wang, Linhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134083/
https://www.ncbi.nlm.nih.gov/pubmed/30033448
http://dx.doi.org/10.1038/s41416-018-0189-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134083/
https://www.ncbi.nlm.nih.gov/pubmed/30033448
http://dx.doi.org/10.1038/s41416-018-0189-4

Ejemplares similares